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ABSTRACT

Pancreatic cancer is a serious disease, one in which the survival rate over five years is
less than 6%. (1) Often, malignant tumors will exhibit uncontrolled proliferation and it is
postulated that they have high metabolic needs.

One of the areas of interest in cancer

metabolism is the unique need for large amounts of polyamines in order to sustain this
uncontrolled proliferation.

Polyamines are organic compounds that all cells need for

proliferation and differentiation. (2) Cells obtain polyamines by manufacture of them directly or
obtain them from the environment through their transport across the cell membrane. When
cancer cells have limited access to polyamines they enter apoptosis, or controlled cell death. In
animal models of cancer, cellular apoptosis can be tracked by measuring tumor weights as well
as histological methods.
It is known that difluromethylornithine (DFMO), a polyamine synthesis inhibitor, has
shown some success in reducing tumor weights. (3) Cells deprived of the ability to manufacture
polyamines will resort to transporting existing polyamines from the environment for their use.
(3) It is believed that a polyamine transport inhibitor (PTI) can be designed and used in
conjunction with DFMO to completely deprive cancer cells of polyamines and increase rates of
apoptosis in tumor cells. Through this study the interaction of DFMO with newly identified PTI
will be analyzed. A mouse model with tumor cells in the pancreas will give a picture of how
cancer cells react to DFMO / PTI in vivo. The findings allow us to postulate how targeted
compounds interact with protein signaling pathways that may be important for regulating
response to inhibitors of polyamine synthesis and/or transport.
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CHAPTER ONE: INTRODUCTION

Problem Statement:

Tumor cells need high levels of polyamines in order to proliferate. Tumor cells obtain
polyamines by either manufacturing them or transport of polyamines from the tissue
environment. Difluoromethylornithine (DFMO) successfully inhibits cells from being able to
manufacture polyamines. However, there is limited information regarding polyamine transport
mechanisms and research into blocking the transport of polyamines into the cells.
Hypothesis:

Polyamine Transport Inhibitors (PTIs) when combined with DFMO will show a
synergistic effect on tumor cell proliferation and/or apoptosis.

Specific Aim 1:

Refine a model to study PTI and its effect on tumor viability and protein
expression/phosphorylation in order to optimize the efficacy of DFMO and PTI therapy

Hypothesis of Specific Aim 1:

Different mechanisms of polyamine pathway inhibition may be needed in order to
observe increased additivity of the combination effects on tumor viability.
Specific Aim 2:

Evaluate

efficacy

of

PTIs

alone

or

in

combination

with

DFMO

using

immunohistochemistry (IHC) markers c-Myc, Raf and ODC.

Hypothesis of Specific Aim 2:

Expression of protein markers by techniques such as immunostaining can be used to
evaluate the efficacy of the PTI / DFMO interaction and their combined effect on tumor viability.
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CHAPTER TWO: BACKGROUND

The pancreas is a gland which has two primary functions. The first is that it secretes
pancreatic juice which both neutralizes the acidic chyme and assists with the digestion of lipids
and proteins immediately after exiting the stomach. It also functions as part of the endocrine
system and secretes the hormones which regulate blood sugar levels. (4) Pancreatic cancer is
difficult to diagnose early due to the lack of definitive symptoms and the anatomical location of
the organ itself. Pancreatic cancer is also hard to treat because usually by detection the cancer
has advanced extensively throughout the organ. Pancreatic cancer is the fourth leading cause of
cancer death in the United States. If diagnosed, individuals have less than 6% survival rate over
five years. (1) Treatments for pancreatic cancer involve surgery, through partial or full removal
of the organ, radiation and chemotherapy, and targeted therapy. (4)
Targeted surgery is not always possible, since typically by detection the cancer has
already spread throughout the organ. Removal of the pancreas has serious detrimental effects on
the quality of life of the patient and is not always a reliable course of action especially if the
cancer has already started to metastasize. (4) Even if successful, such a procedure requires
lifelong dietary restrictions, digestive system supplementation and strict hormonal control.
Radiation and chemotherapy are not typically successful in treatment of pancreatic cancer. (5)
Targeted therapy of cancerous cells within the pancreas through different combinations of drugs
has shown some promise. (1) Although still investigational, inhibiting the cells’ ability to obtain
polyamines, a required component to their proliferation, may be a novel drug targeting strategy.
(6) (7)
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Polyamines are organic compounds that contain two or more amino groups, rather than
the single amino group associated with the N-terminus of amino acids. They are required for cell
proliferation and differentiation. (8) The three polyamines that eukaryotic organisms require are
putrescine, spermidine and spermine, their structures are shown in Figure 1. Elevated levels of
polyamines in tumors have been established in several cancers, including colorectal and
pancreatic cancers. The role of polyamines in the initiation or progression of these cancers has
not been established. (1) There are two methods in which cells can obtain polyamines. The first
is that they can manufacture them directly.

The second method is that they can obtain

polyamines from the environment through transport across the cell membrane. Without adequate
levels of polyamines, cancer cells initiate apoptosis, or programmed cell death. (9) Methods that
block or neutralize either the synthesis or the transport method of obtaining polyamines has been
a focus of research in order to force cancer cells to enter the apoptotic pathway.

Figure 1 : Polyamine Structures for the Three Polyamines Eukaryotes Require

The first method by which cells obtain polyamines is through direct synthesis. Ornithine
decarboxylase (ODC) is the rate limiting enzyme for polyamine synthesis and is inhibited by
DFMO. (1) DFMO is a drug that has been FDA approved and can be given over long periods of
times at low doses without causing detectable side effects. (10) The amino acid ornithine is
decarboxylated by ODC into the first polyamine, putrescine (Figure 1). Subsequently a propyl4

amine group is added to putrescine by spermidine synthase to form the second polyamine,
spermidine. A second propyl-amine is added to spermidine through spermine synthase, resulting
in the third polyamine, spermine. An illustration of the mechanism is shown below in Figure 2.
Assessment of tumor progression can be done in several ways.

Figure 2 : Polyamine Synthesis Mechanism (11)

The most basic method analyzes tumor weights. DFMO has been shown to decrease
pancreatic tumor weights in mice by up to 43%, as seen in Figure 5. Other ways to track
progression of tumors include using histopathology analysis. Proliferation markers can be seen
in cells where cancer cells are actively growing and dividing, whereas apoptosis markers may be
observed in cells that are dying.

DFMO inhibits tumor progression and modulates ODC
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signaling and cell proliferation, resulting in high levels of apoptotic markers and low levels of
proliferation markers. (1)
The second method by which cells obtain polyamines is via the transport of them from
the environment across the cell membrane via a polyamine transporter and is shown below in
Figure 3.

Research has demonstrated that there are various recognition sites on the cell

membrane which identify polyamines and signal the cells to uptake it through membrane
transport mechanisms. For example, cells identify the polyamines putrescine, spermidine and
spermine through recognition sites on the cell. One mechanism for uptake is accomplished via
binding with human organic cation transporter 2 (hOCT2). (12) Although these receptors have
been identified, research into their inhibition has been limited. It is believed that PTI’s can be
designed to block these receptors and prevent cells from being able to acquire polyamines from
the cellular microenvironment. (13)

This process when combined with the use of DFMO

restricts cellular access to polyamines further than with DFMO alone, increases cell apoptotic
markers, and drug treatment has been demonstrated to work in vitro.

Figure 3 : Polyamine Import through a Polyamine Transporter
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Two markers have already been evaluated, the proliferation maker Ki-67 and the
apoptotic marker Caspase-3. The Ki-67 marker detects areas of tumors which are considered
healthy and growing. Caspase-3 plays a critical role in the apoptotic pathway and reveals parts
of the tumor that are either dead or in final stages of apoptosis. The absence of Ki67 and/or
presence of Caspase-3 can be used to test the tumor response to new drug treatments (DFMO,
PTI & GW5074) that are responsible for an effect on these protein markers. In addition, three
proteins have been selected for further study, including ODC, c-Myc, and c-Raf. These proteins
have been selected to more thoroughly assess the status of the microenvironment that exists
within the tumors. Since ODC is a rate limiting enzyme for cellular production of polyamines,
an antibody for ODC has been selected to study the effects that DFMO is having on the cellular
microenvironment. The c-Myc oncogene is overexpressed in cancer cells, and its associated cMyc protein has been selected as a marker to better understand its role within the tumor
environment. In addition, c-Myc is a trans-activating transcriptional factor for ODC. (10)
Compound GW5074 is an inhibitor of the oncogene c-Raf, which plays a role in the cellular
regulation processes’ and is overexpressed in tumor cell environments. (14) Since c-Raf is
active when phosphorylated at the Serine 338 site, an antibody to evaluate c-Raf(Ser338) has
been selected as well. (15) The overall pathway that this thesis is based on is shown below in
Figure 4.
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Figure 4 : Polyamine Synthesis and Transport Pathway with Inhibitors Being Studied

Immunohistochemistry (IHC) will be conducted to give a visual analysis of the
expression of these three proteins, the general concentration, and their location in tumors. This
will be conducted for the immune compromised (nude) mouse / L3.6pl experiment since the
antibodies are selected and optimized for this experiment.
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CHAPTER THREE: PRELIMINARY DATA

A preliminary experiment has been conducted using immune deficient nude mice.
Tumors were induced by injecting 0.5x106 human pancreatic L3.6pl tumor cells into the mouse
pancreas. After a week, treatments were started. The percentage of DFMO in drinking water for
subsequent treatments was determined by analyzing tumor weights on four groups of mice as
shown below in Figure 5. The tumor weights using 1% DFMO were approximately 30% less
than the untreated group. Although the 3% DFMO showed that tumor weights were even further
reduced by 40% less than the untreated group, statistically there wasn’t a significant advantage to
use of more than 1% DFMO in future combination experiments. In fact it may be possible to
conduct further experiments to optimize less DFMO concentration, if needed.

Figure 5 : DFMO Percentages and Tumor Weight for the L3.6pl In Vivo Model (16)

Histological markers for Ki67 and Caspase-3 are shown below in Figure 6, Figure 7, and
Figure 8. It can be seen that the proliferation marker Ki67 (brown color in the cell nucleus) is
more prevalent in the untreated tumor vs. the DFMO treated model, while the apoptotic marker
9

Caspase-3 (also brown in color) is more prevalent in the DFMO treated as compared to the
untreated tumors. The 5X and 10X in the figures indicate the magnification that the images were
taken at for the same region of the tumors.

Figure 6 : Untreated L3.6pl Tumor Histological Markers for Baseline Proliferation and Apoptosis
(16)

Figure 7 : 1% DFMO Treated L3.5pl Tumor Histological Markers for Potentially More Apoptosis
and Less Cell Proliferation (16)
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Figure 8 : 3% DFMO Treated L3.6pl Tumor Histological Markers for Potentially More Apoptosis
and Less Cell Proliferation (16)

The same methodology used to determine the concentrations of DFMO was applied to
determine the concentrations of PTI and GW5074 in nude mice with L3.6pl pancreatic tumor
cells.

The PTI used was Trimer44NMe, which is a benzene substituted with three N-

methylhomospermidine motifs. It has shown promise by inhibiting the uptake of spermidine in
L3.6pl cells in vitro. (7) The chemical structures of DFMO, Trimer44NMe and GW5074 are
shown in Figure 9.

Figure 9 : Structures of DFMO (17), Trimer44NMe (7) and GW5074 (17)
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The trimer44NMe PTI was tested and the determined maximum tolerated dose was 5
mg/kg body weight.

The GW5074 dosage of 1mg/kg was used, which is within the

concentration that was recommended by the drug manufacturer of 0.5mg/kg – 10mg/kg. (18)
Both the PTI and GW5074 were administered intraperitonially via injection, whereas the DFMO
was administered through the drinking water. Figure 10 shows the results which demonstrate
that increasing the concentration of GW5074 effects tumor weights. However, the same was not
seen for the trimer44NMe PTI.

Figure 10 : L3.6pl Ex Vivo Tumor Weights in Response to trimer44NMe (PTI) and GW5074
Treatments (16)
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Figure 11 : Nude Mice with L3.6pl Derived Tumor Exhibit Anti-Growth Responsiveness to Single
and Double Treatments Compared to Untreated Conditions (16)

The experiment in Figure 11 used 1mg/kg of GW5074 and equimolar concentrations of
the trimer44NMe (PTI, 1.85 mg/kg) for the single and combination treatments. The molecular
weight of the trimer44NMe PTI (as its nonahydrochloride salt) is 962.19 g/mol and the
molecular weight of the GW5074 compound is 520.94 g/mol, respectively. The 1mg/kg of
GW5074 was equivalent on a molar basis to a 1.85 mg/kg dose of the trimer44NMe PTI and is
below the maximum tolerated dose of 5mg/kg for the trimer 44NMe PTI.
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CHAPTER FOUR: MATERIALS AND METHODS

Tissue Preparation
After the experiment was completed tumor tissues were harvested, placed in 10% neutralbuffered formalin (Leica Surgipath) for preservation, and then processed for further study. After
the tissue was fixed for at least four hours, and more often greater than 24 hours, it was ready for
processing. Processing was needed in order to infiltrate the tissue with paraffin wax so that it
could be uniformly sectioned during slide preparation. This was accomplished with a Leica
ASP300 S Vacuum Tissue Processor, thorough a programmatic series of steps that involved
soaking the tissue in cycles of ethanol, xylene and paraffin wax. Upon completion of processing,
the infiltrated tissue was placed in a mold filled with paraffin through the use of a Leica EG1150
Tissue Embedding Center, and the blocks were then allowed to harden for at least 24 hours prior
to use.

Once tissue had been embedded in paraffin, the block could be stored at room

temperature.
Slide Preparation
Slides were prepared by placing the paraffin embedded tissue block on a Leica RM2235
Manual Rotary Microtome. The microtome allows for consistent and fine sectioning of tissue.
Layers of tissue, 5 microns thick, were cut and floated in a 40°C hot water bath. The hot water
bath allowed for the paraffin to soften but not melt completely. Sections were then guided onto a
poly-l-lysine coated glass microscope slide (Thermo/Fisher Scientific), while in the water bath.
This type of slide allows for tissue to adhere to the surface of the glass. Once the tissue was
14

placed on the slide, they were then heated to 65°C for thirty minutes to dry the slides and ensure
that the tissue properly adhered.
Antibody Optimization
Prior to running an experiment, selected primary antibodies were optimized for dilution.
Too much antibody used for staining purposes may bind non-specifically as well as result in
extensive background staining. Too little antibody may result in light or no staining at all.
Antibody slides from the untreated control group were selected for the optimization procedure.
Depending on the antibody, various levels of dilution were selected based on the data sheets
provided by the manufacturer. The antibodies used and dilution levels are listed below in Table
1.
Table 1 : Dilutions Selected to Optimize Antibodies for Experimental Staining

Antibody
(source)

Dilutions

ODC
(Origene)

1:50
1:100
1:250
1:250
1:500
1:1000
1:100
1:250
1:500

c-Myc
(Abcam)
c-Raf
(Bioss)

Tissue staining can vary depending on time and concentration of agents. Consistency
between each slide can be better maintained by using an automated method. Slides were placed
in the Leica Bond Max immunostainer. This instrument prepares slides for staining by removing
15

the paraffin wax from the tissue sections and treating with an epitope retrieval agent (either
Citrate or EDTA).

After preparation, staining the tissue for the appropriate antibody and

counterstaining the tissue with hematoxylin to show the cell nuclei was conducted. For both the
optimization and experiment, each slide was individually bar coded and scanned into the
instrument to dictate the desired antibody, as well as the type of epitope retrieval agent using
the Leica Bond software. Microscope slides were prepared for coverslipping after antibody
staining.

The tissue sections were dehydrated by placing the slides in an increasing

concentration of ethanol followed by xylene. This procedure was immediately followed by
applying Cytoseal-60 (Richard-Allan Scientific) and a coverslip. The slides were then imaged
on a Leica DM 2000 microscope with digital DFC 295 camera and Leica imaging software.

Slide Staining
Once antibody dilution levels were determined, the Leica Bond Max immunostainer was
used to conduct staining on all treatment groups for each desired antibody. The dilution levels
and epitope retrieval used for this experiment are shown in Table 2.
Table 2 : Selected Antibody Dilution and Epitope Retrieval

Antibody
(source)
ODC
(Origene)
c-Myc
(Abcam)
c-Raf
(Bioss)

Dilution

Epitope
Retrieval

1:50

Citrate

1:50

Citrate

1:100

EDTA
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The 1:50 dilution was selected for c-Myc even though this was below the low end used in
optimization due to light staining seen. Again slides were dehydrated, cover slipped, and then
imaged. Once images were obtained Microsoft word was used to create the composite images
which are shown and discussed below in chapter five.
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CHAPTER FIVE: RESULTS AND ANALYSIS

Immunohistochemistry

Immunohistochemistry was conducted on L3.6pl tumors and the stained slides were
imaged for each of the treatment groups to determine protein levels for c-Raf, c-Myc and ODC.
Phosphorylated c-Raf was evaluated because it is a protein kinase that mediates the MAPK
protein signaling cascade. Images obtained at 10X magnification from the six treatment groups
are shown in Figure 12 below. The groups that were treated with GW5074 show a significant
decrease in phosphorylated c-Raf. This is expected since GW5074 acts as an inhibitor to Raf.
The groups that were not treated with GW5074 did not show decreased levels of phosphorylated
c-Raf.

Figure 12 : Decreased Phosphorylated c-Raf Immunohistochemistry Detected in GW5074
Treatment Groups
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The transcription factor c-Myc was also evaluated at 10X magnification and results are
shown below in Figure 13. Since Raf is upstream of c-Myc (see Figure 3), it is expected that
there will be a decrease of c-Myc levels in groups that were treated with the c-Raf inhibitor,
GW5074. This is the trend that was observed. Other treatment groups that had been treated with
DFMO showed a slight decrease in the expression of c-Myc, although not as profound as those
treated with GW5074. It has been observed that DFMO plays a role in the down regulation of cMyc in certain cell types. (19) It is possible that that could be happening with the L3.6pl cells
used.

Figure 13 : c-Myc Immunohistochemistry Showed Decreased Expression that was Most Apparent
in Response to GW5074

The enzyme ODC was also evaluated through immunohistochemistry. The results of the
ODC staining at 10X magnification are shown below in Figure 14. As with the c-Raf and c-Myc
staining, ODC levels are considerably lower in the treatment groups that were given GW5074.
19

Again, this is expected because c-Myc is a transcription factor which affects the expression
levels of ODC. The group treated with DFMO alone still shows staining comparable to the
untreated group. This is also expected since DFMO only inhibits the ODC enzyme from
synthesis of putrescine, but does not stop expression. As a result ODC is being expressed in
groups treated with DFMO, however it may accumulate in its inactive form. (19). Unlike c-Raf,
there is no known commercial antibody to detect specific phosphorylation of ODC.

The

treatment groups with the PTI show even higher levels of ODC expression. This is most likely
due to the fact that the cellular capability to import polyamines has been inhibited, and these
cells now depend completely on the synthesis of ODC to manufacture polyamines. As a result of
this dependency, ODC is shown to be upregulated in the tumors that have been treated with the
PTI. The group that is treated with DFMO and PTI shows a decrease in levels of ODC from
those treated with the PTI alone, demonstrating that this is a synergistic effect when both DFMO
and the PTI are used together.

Figure 14 : ODC Immunohistochemistry Exhibited Decreased Expression in Response to GW4074
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In Figure 15 a composite side by side image is provided for comparison between different
antibody staining of each group. All images were taken of the same region of the tumor for each
treatment group.
p-c-Raf
1:100 ER2

c-Myc
1:50 ER1

ODC
1:50 ER1

Untreated

1%DFMO

GW5074

PTI Only

(T

1% DFMO &
GW5074

1% DFMO &
PTI

Figure 15 : Composite Image of All Staining Images
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CHAPTER SIX: FUTURE EXPERIMENT

Although not yet examined for protein markers for c-Raf or ODC, the research laboratory
also has a pancreatic model whereby mouse Panc02 pancreatic tumor cells were injected into
immune competent C57Bl/6 mice. In this experiment seven groups of mice were studied. The
treatment and results on tumor weights are shown below in Figure 16. It can be seen that in
groups treated with 1% DFMO, tumor weights were reduced by approximately 50%. Tumor
weights were even further reduced in the groups that were treated jointly with 1% DFMO and
PTI. Finally, groups treated with 1% DFMO, PTI and GW5074 exhibited the smallest tumors..

Tumor weight (g)

1.5

1.0

0.5

W
nl
50
y
7
4
1%
on
1%
D
FM ly
D
1%
O
FM
+P
D
FM O+
TI
G
O
W
+P
50
TI
+ G 74
W
50
74

IO
G

PT

D
1%

U

nt

re

at

FM

O

ed

0.0

Figure 16 : C57Bl/6 Mice with Panc02 Derived Tumor Exhibit Response to 1% DFMO alone and in
combination with PTI and/or GW5074 (16)

Histological markers for Ki67 in each of the groups studied are shown at 40X
magnification below in Figure 17. It can be seen that there is significant Ki67 present in the
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untreated group compared to the treated groups. Only GW5074 by itself failed to show a
significant reduction of Ki67.

Figure 17 : Panc02 Tumors have Decreased Staining Against Ki67 Proliferation Marker in the
Presence of Hematoxylin-Nuclear Stain (16)

Histological markers for c-Myc in each of the groups are shown at 40X magnification
below in Figure 18. It can be seen that there is significant c-Myc present in the untreated group
compared to the treated groups.

23

Figure 18 : Panc02 Tumors have Decreased Staining Against c-Myc Nuclear Marker with in the
Presence of Hematoxylin-Nuclear Stain (16)

The next phase in this series of experiments to study PTIs when combined with DFMO is
to follow up with the orthotopic mouse model with Panc02 (mouse cell line) and also to test
tumorigenicity of Panc02 in the Nude immunocompromised mouse model. A determination
needs to be made if the concentration of DFMO can be lowered in order to better assess and
identify if there truly is synergy in combination treatments with DFMO and PTI’s. As a result all
experiments previously conducted, the Panc02 cell line may need to be repeated with 0.5%
DFMO and 0.2% DFMO. The experiment also needs to assess the effect of survival of animals
with combination treatments, over those treated with single agents alone, and to delineate the
effect that the immune system may have on tumor cell proliferation and/or apoptosis when
combined with PTIs and DFMO.
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In these experiments seven groups of five mice orthotopically injected with a mouse
pancreatic tumor cell line Panc02 will be treated as shown in Table 3 below. These mice will
receive between 0.2-1% of DFMO in drinking water. They will be injected intraperitonally with
PTI and GW5074. GW5074 will be delivered at a dosage of 1mg/kg body weight, while PTI
will be delivered at an equimolar dosage. They will be injected five days per week for two
weeks, which is modeled after the C57Bl/6 experiment previously conducted. Upon completion
of the experiment tumor efficacy will be analyzed based on various markers, including Ki67,
Caspase-3, ODC, c-Myc, and c-Raf.

Table 3 : Future Experimental Treatment Groups

Mouse Group

DFMO

PTI

GW5074

1
2

X

3

X

4

X

5

X

6

X

7

X

X
X
X

X

Table 1: Experimental Treatment Groups. Treatment groups that receive DFMO will be injected
with 1%, 0.5% and 0.2% DFMO depending on the respective experiment.
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These results will then be compared to the C57Bl/6 (Panc02) experiment to better
understand the role that the immune system is having on the synergistic effects in the various
treatment groups. This experiment will demonstrate if low dose of DFMO when combined with
PTI can have an additive effect on tumor viability. The experiment will be terminated when the
health assessment indicates tumor stress.
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CHAPTER SEVEN: CONCLUSION

Pancreatic cancer is a serious disease, one in which the survival rate over five years is
less than 6%. (1) In order for pancreatic tumors to exhibit uncontrolled proliferation they have
high metabolic needs and require large amounts of polyamines to sustain this uncontrolled
growth.

There are two methods known in which cells obtain polyamines, through direct

synthesis and transport. DFMO is a polyamine synthesis inhibitor which has shown some
success in reducing tumor weights. GW5074 is an inhibitor of c-Raf, an upstream protein which
plays a role in the synthesis of polyamines as well as the apoptotic pathway. Trimer44NMe, a
PTI has also shown promise in vitro. It is believed that by combining polyamine synthesis
inhibitors with polyamine transport inhibitors a synergistic effect on proliferation and/or
apoptosis would be demonstrated.
By investigating the expression of protein markers the efficacy of the PTI / DFMO
interaction and their combined effect on tumor viability was studied. The protein markers
selected for study were c-Raf, c-Myc and ODC. The relationship between the markers being
studied and the treatments used was shown in Figure 4. It was believed that by inhibiting c-Raf
with GW5074 reduced levels of both c-Myc and ODC would be seen, which was the case.
When treated with the PTI, higher levels of ODC were observed, most likely due to the exclusive
cellular dependence on synthesis of polyamines. A synergistic effect was observed in the
treatment groups that received both a polyamine synthesis inhibitor as well as a polyamine
transport inhibitor. Through data obtained from this study future experiments can be modeled
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and conducted which will more accurately determine the appropriate levels of DFMO, GW5074
and Trimer44NMe to optimize treatments in advance of clinical trials.
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APPENDIX: ANTIBODY DATASHEETS
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